Aims: To Determine Prognostic factors for overall survival in patients withmetastatic gastric cancer (mGC).Methods: A retrospective descriptive study on patients with stage IV gastric cancerin the Oncology Center of Hue central hospital, Viet Nam, from 2015 to 2020. Beforeinitiating treatment, demographic, clinical, and laboratory features as well as treatmentmethods were documented. The Kaplan - Meir test was used to estimate overallsurvival. Prognostic factors of survival were identified using the Cox model.Results: There were atotal of 167 patients, witha median age of 58. The majorityof patients had BM Iunder 18.5 kg/m2(64.1%) and KPS above 80 (86.8%) prior totreatment. The most common clinical symptom was epigastric pain (73.7%). 86.2% ofpatients had serum albumin levels below 35g/L. 64.0% of patients underwent palliativesurgery, including 69.2% who had gastrectomy. The chemotherapy rate was 59.9%,with 93.0% multidrug cytotoxic regimens. The median survival was 11 months. Byusing multivariate analysis, serum albumin (95%CI: 1.055 - 3.190, p = 0.032), palliativesurgery (95%CI: 0.407 - 0.873, p = 0.008) and multidrug chemotherapy regimens(95%CI: 0.424 - 0.920, p = 0.017) were independent prognostic factors.Conclusion: Patients with stage IV gastric cancer have poor overall survival at 11months. Lowserum albumin, palliative surgery, and doublet/triplet chemotherapy werefour independent prognostic factors